# STATEMENT 2025

# Ferring Pharmaceuticals announces optimisation of operations to accelerate growth

By [celia](/content/author/celia/index.html) in [STATEMENT 2025](/content/category/statement-2025/index.html) on 07 October 2025

# Ferring announces new Ambition, Enterprise Model and Executive Committee composition to accelerate growth and innovation

By [celia](/content/author/celia/index.html) in [STATEMENT 2025](/content/category/statement-2025/index.html) on 10 September 2025

Ferring announces new Ambition, Enterprise Model and Executive Committee composition to accelerate…

# Ferring Statement on Minirin® / Octostim® / DDAVP® / Stimate® (desmopressin) Nasal Spray

By [celia](/content/author/celia/index.html) in [STATEMENT 2025](/content/category/statement-2025/index.html), [STATEMENT 2022](/content/category/statement-2022/index.html) on 21 June 2022

Following the detection of out-of-specification results during testing, in 2020 Ferring initiated a precautionary voluntary global recall of all batches of the following products: Minirin® (desmopressin) Nasal Spray 0.1 mg/ml…

This page is not intended for patients or for members of the general public. It is only intended to be used by healthcare professionals.